Wednesday, April 15, 2015

Drugs in Clinical Pipeline: 4SC-202

4SC-202 [(E)-N-(2-aminophenyl)-3-(1-((4-(1-methyl-1H-pyrazol-4-yl)phenyl)sulfonyl) -1H-pyrrol-3-yl)acrylamide] is an oral anti-cancer compound and possesses a unique mode of action consisting of both epigenetic regulation and cancer stem cell targeting.  4SC-202 is a selective inhibitor of LSD1 and HDACs 1, 2, and 3 with a unique combination of anti-cancer mode of actions, namely epigenetic regulation and targeting of cancer stem cells.